PAN-TB Collaboration Announces Novel TB Drug Regimens Trial


The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-profit, philanthropic, and private sector partners for a common mission to develop novel TB medicines that are better-tolerated, shorter in duration, and simpler to use than existing options. The collaboration includes members such as Evotec, GSK, Janssen, Otsuka, TB Alliance, the Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Bill & Melinda Gates Foundation.

The Phase 2 study announced by Gates MRI last week will evaluate 2 novel drug regimens comprising of 5 anti-TB chemical entities, some of which are currently approved for treatment of TB and new chemical entities to the treatment of TB. The anti-TB agents are:

The two drug regimens under investigation in this clinical trial are:

  • DBOS – Delamanid, Bedaquiline, OPC-167832, and Sutezolid
  • PBOS – Pretomanid, Bedaquiline, OPC-167832, and Sutezolid

The 5 drugs and drug candidates are owned by 4 of the PAN-TB consortium’s members: Janssen Pharmaceutica (Bedaquiline), Otsuka Pharmaceutical (Delamanid & OPC-157832), TB Alliance (Pretomanid & Sutezolid), and Gates MRI (Sutezolid). These 4 members and the Bill & Melinda Gates Foundation have signed a joint development agreement (JDA) to investigate these novel regimens in a Phase 2 clinical trial that will be conducted by the Gates MRI. The PAN-TB consortium’s goal is to identify a regimen that is suitable for phase 3 development.

Last year, the WGND produced an episode of it's podcast, The Dose, on the topic of the PAN-TB Collaboration. Listen to this episode by clicking here or on Vimeo

To read more about this announcement please visit below:


More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...